Apple May Break Into The Hearing Aid Industry

September 17, 2024 by Jenny List 33 Comments

When the entry of a tech giant such as Apple into a market represents its liberation from exploitation, that market must be really broken, yet the reported FDA approval of the hearing aid feature in the latest AirPod earbuds seems to represent just that. The digital hearing aid business is notorious for its sharp sales practices and eye-watering prices, so for all Apple’s own notoriety the news might actually represent a leap forward for consumers in that sector. We have to ask though, if Apple of all people are now the Good Guys, where has the world of electronics gone so badly wrong?

Your grandparents decades ago would have had a simple analogue hearing aid if they had one, usually a small transistor circuit and perhaps with some kind of analogue filtering. Digital aids with DSP algorithms to pick out speech arrived some time in the 1990s, and from there evolved a market in which their high prices increasingly didn’t match the cost of the technology or software involved. At least in the UK, they were sold aggressively to older people as less cumbersome or better than the National Health Service aids, and if you had an older person in the family it was routine to see pages and pages of targeted junk mail offering dubious financial schemes to pay for them.

The question then, given that a modern hearing aid has a relatively cheap microcontroller and DSP at its heart, why has the open source community not risen to the challenge? The answer is that they have, though the Tympan seems an over-expensive trinket for what it is and the LoCHAid and Open Speech Platform seem to have sunk without trace. Can we do better?

Header: Gregory Varnum, CC BY-SA 4.0 .

Hack Your Eyesight With High Tech Bifocals

September 16, 2024 by Al Williams 32 Comments

As we get older, our eyes get worse. That’s just a fact of life. It is a rite of passage the first time you leave the eye doctor with a script for “progressive” lenses which are just fancy bifocals. However, a new high-tech version of bifocals promises you better vision, but with a slight drawback, as [Sherri L. Smith] found.

Remember how users of Google Glass earned the nickname “glassholes?” Well, these new bifocals make Google Glass look like a fashion statement. If you are too young to need them, bifocals account for the fact that your eyes need different kinds of help when you look close up (like soldering) or far away (like at an antenna up on a roof). A true bifocal has two lenses and you quickly learn to look down at anything close up and up to see things far away. Progressives work the same, but they transition between the two settings instead of having a discrete mini lens at the bottom.

The new glasses, the ViXion01 change based on what you are looking for. They measure range and adjust accordingly. For $555, or a monthly rental, you can wear what looks like a prototype for a Star Trek visor and let it deduce what you are looking at and change its lenses accordingly.

Of course, this takes batteries that last about ten hours. It also requires medical approval to be real glasses and it doesn’t have that, yet. Honestly, if they worked well and didn’t look so dorky, the real use case might be allowing your eye doctor to immediately download a new setting as your vision changes. How about you? How much odd headgear are you willing to wear in public and why?

Glasses have a long strange history. While a university prototype we saw earlier was not likely to win fashion awards, they did look better than these. Maybe.

Five colors of Cast21 on five different wrists.

Cast21 Brings Healing Into 2024

September 14, 2024 by Kristina Panos 16 Comments

It takes but an ill-fated second to break a bone, and several long weeks for it to heal in a cast. And even if you have one of those newfangled fiberglass casts, you still can’t get the thing wet, and it’s gonna be itchy under there because your skin can’t breathe. Isn’t it high time for something better?

Enter Cast21, co-founded by Chief Technical Officer [Jason Troutner], who has been in casts more than 50 times due to sports injuries and surgeries. He teamed up with a biomedical design engineer and an electrical engineer to break the norms associated with traditional casts and design a new solution that addresses their drawbacks.

So, how does it work already? The latticework cast is made from a network of silicone tubes that harden once injected with resin and a catalyst mixture. It takes ten seconds to fill the latticework with resin and three minutes for it to cure, and the whole process is much faster than plaster or fiberglass.

This new cast can be used along with electrical stimulation therapy, which can reduce healing time and prevent muscle atrophy.

Cast21 is not only breathable, it’s also waterproof, meaning no more trash bags on your arm to take a shower. The doctor doesn’t even need a saw to remove it, just cut in two places along the seam. It can even be used as a splint afterward.

It’s great to see advancements in simple medical technologies like the cast. And it looks almost as cool as this 3D-printed exoskeleton cast we saw ten years ago.

Thanks to [Keith Olson] for the tip!

Second Human Neuralink Brain Implant Recipient Uses It For CAD And Videogaming

August 22, 2024 by Maya Posch 55 Comments

As Neuralink works towards getting its brain-computer interface technology approved for general use, it now has two human patients who have received the experimental implant. The second patient, [Alex], received the implant in July of 2024 and is said to be doing well, being able to play games like Counter Strike 2 without using his old mouth-operated controller. He’s also creating designs in Fusion 360 to have them 3D printed.

This positive news comes after the first patient ([Noland Arbaugh]) suffered major issues with his implant, with only 10-15% of the electrodes still working after receiving the implant in January. The issue of electrode threads retracting was apparently a known issue years prior already.

We analyzed Neuralink’s claims back in 2019, when its founder – [Elon Musk] – was painting lofty goals for the implant, including reading and writing of brains, integration with AIs and much more. Since that time Neuralink has been mostly in the news for the many test animals which it euthanized during its test campaign prior to embarking on its first human test subjects.

There also appears a continuing issue with transmitting the noisy data from the electrodes, as it is far more data than can be transmitted wirelessly. To solve this seemingly impossible problem, Neuralink has now turned to the public with its Neuralink Compression Challenge to have someone make a miraculous lossless compression algorithm for it.

With still many challenges ahead, it ought to be clear that it will take many more years before Neuralink’s implant is ready for prime-time, but so far at least it seems to at least make life easier for two human patients.

Continue reading “Second Human Neuralink Brain Implant Recipient Uses It For CAD And Videogaming” →

A giemsa stained blood smear from a person with beta thalassemia (Credit: Dr Graham Beards, Wikimedia Commons)

Potential Cure For All Of England’s Beta Thalassemia Patients Within Reach

August 10, 2024 by Maya Posch 6 Comments

Beta thalassemia and sickle cell are two red blood cell disorders which both come with massive health implications and shortened lifespans, but at least for UK-based patients the former may soon be curable with a fairly new CRISPR-Cas9 gene therapy (Casgevy) via the UK’s National Health Service (NHS). Starting with the NHS in England, the therapy will be offered to the approximately 460 β thalassemia patients in that part of the UK at seven different NHS centers within the coming weeks.

We previously covered this therapy and the way that it might offer a one-time treatment to patients to definitely cure their blood disorder. In the case of β thalassemia this is done by turning off the defective adult hemoglobin (HbA) production and instead turning the fetal hemoglobin (HbF) production back on. After eradicating the bone marrow cells with the defective genes, the (externally CRISPR-Cas9 modified) stem cells are reintroduced as with a bone marrow transplant. Since this involves the patient’s own cells, no immune-system suppressing medication is necessary, and eventually the new cells should produce enough HbF to allow the patient to be considered cured.

So far in international trials over 90% of those treated in this manner were still symptom-free, raising the hope that this β thalassemia treatment is indeed a life-long cure.

Top image: A giemsa stained blood smear from a person with beta thalassemia. Note the lack of coloring. (Credit: Dr Graham Beards, Wikimedia Commons)

The BiVACOR Total Artificial Heart: A Maglev Bridge To Life

July 28, 2024 by Maya Posch 28 Comments

The BiVACOR THA hooked up with the CTO Dianiel Timms in the background. (Credit: BiVACOR)

Outside of the brain, the heart is probably the organ that you miss the most when it ceases to function correctly. Unfortunately, as we cannot grow custom replacement hearts yet, we have to keep heart patients alive long enough for them to receive a donor heart. Yet despite the heart being essentially a blood pump, engineering even a short-term artificial replacement has been a struggle for many decades. A new contender has now arrived in the BiVACOR TAH (total artificial heart), which just had the first prototype implanted in a human patient.

Unlike the typical membrane-based pumps, the BiVACOR TAH is a rotary pump that uses an impeller-based design with magnetic levitation replacing bearings and theoretically minimizing damage to the blood. This design should also mean a significant flowrate, enough even for an exercising adult. Naturally, this TAH is only being tested as a bridge-to-transplant solution, for patients with a failing heart who do not qualify for a ventricular assist device. This may give more heart patients a chance to that donor heart transplant, even if a TAH as a destination therapy could save so many more lives.

The harsh reality is that the number of donor hearts decreases each year while demand increases, leading to unconventional approaches like xenotransplantation using specially bred pigs as donor, as well as therapeutic cloning to grow a new heart from the patient’s own cells. Having a universal TAH that could be left in-place (destination therapy) for decades would offer a solid option next to the latter, but remains elusive. As shown by e.g. the lack of progress with a TAH like the ReinHeart despite a promising 2014 paper in a bovine model.

Hopefully before long we’ll figure out a reliable way to fix this ‘just a blood pump’ in our bodies, regardless of whether it’s a biological or mechanical solution.

Software Bug Results In Insulin Pump Injuries, Spurs Recall

May 11, 2024 by Dan Maloney 24 Comments

Managing Type 1 diabetes is a high-stakes balancing act — too much or too little insulin is a bad thing, resulting in blood glucose levels that deviate from a narrow range with potentially dire consequences on either side. Many diabetics choose to use an insulin pump to make managing all this easier, but as a recent recall of insulin pump software by the US Food and Drug Administration shows, technology isn’t foolproof.

Thankfully, the recall is very narrow in scope. It’s targeted at users of the Tandem t:slim X2 insulin pump, and specifically the companion application running on iOS devices. The mobile app is intended to run on the user’s phone to monitor and control the pump. The pump itself is a small, rechargeable device that users often keep on their belt or tucked into a pocket that delivers a slow, steady infusion of insulin during the day, plus larger bolus doses to compensate for meals.

But version 2.7 of the t:connect mobile app can crash unexpectedly, and on iOS devices, that can lead to the OS continually relaunching it. Each time it does this, the app tries to reconnect with the pump via Bluetooth, which eventually runs down the battery in the pump. Once the battery is dead, no more insulin can be delivered, potentially leading to a condition called hyperglycemia (“hyper” meaning an excess, “gly” referring to sugar, and “emia” meaning presence in blood — excess sugar in the blood.)

Untreated hyperglycemia can progress to a much more serious state called diabetic ketoacidosis, which can lead to coma and death. Thankfully, nobody has suffered that fate from this bug, but the FDA has received over 200 reports of injuries, hence the recall. Tandem sent out a notice to all affected customers back in March to update their apps, but it’s still possible that some users didn’t get the message.

Apart from the human cost of this bug, there’s a lesson here about software design and unintended consequences. While it intuitively seems like a great idea to automatically relaunch a crashed app, especially one with a critical life-safety function, in hindsight, the better course might have been to just go into a safe mode and alert the user with an alarm. That’s a lesson we’ve learned by exploring space, and it seems to apply here as well.

Images: AdobeStock, Tandem Diabetes